MKI67 and cancer: The weaker inhibition of tumor volume for the combined treatment with J2 or Uprosertib relative to that of Ki67-positive cells may have occurred because J2 or Uprosertib did not affect immune cells like CD3 positive cells, which account for a part of the tumor volume, but only affected cancer cells (Supplementary Fig. S6A).